Actuate Therapeutics’ (ACTU) “Buy” Rating Reiterated at HC Wainwright

Actuate Therapeutics (NASDAQ:ACTU)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $15.00 price target on the stock.

A number of other equities analysts have also recently issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Actuate Therapeutics in a research report on Friday, March 27th. Wall Street Zen raised Actuate Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Actuate Therapeutics currently has an average rating of “Hold” and a consensus target price of $17.50.

Actuate Therapeutics Price Performance

Actuate Therapeutics stock traded down $0.24 during trading hours on Monday, reaching $2.38. The company had a trading volume of 56,826 shares, compared to its average volume of 113,462. The company has a 50-day moving average price of $2.56 and a 200 day moving average price of $4.65. The firm has a market cap of $56.43 million, a price-to-earnings ratio of -2.45 and a beta of 0.92. Actuate Therapeutics has a 12-month low of $1.58 and a 12-month high of $11.99.

Actuate Therapeutics (NASDAQ:ACTU) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01). As a group, research analysts expect that Actuate Therapeutics will post -0.8 earnings per share for the current year.

Hedge Funds Weigh In On Actuate Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ACTU. Voss Capital LP increased its position in shares of Actuate Therapeutics by 213.2% during the third quarter. Voss Capital LP now owns 896,278 shares of the company’s stock valued at $5,996,000 after buying an additional 610,138 shares during the period. Texas Capital Bank Wealth Management Services Inc purchased a new position in shares of Actuate Therapeutics during the fourth quarter valued at about $579,000. BIOS Capital Management LP increased its position in shares of Actuate Therapeutics by 0.9% during the third quarter. BIOS Capital Management LP now owns 10,049,996 shares of the company’s stock valued at $67,234,000 after buying an additional 84,917 shares during the period. Geode Capital Management LLC grew its stake in Actuate Therapeutics by 252.5% in the second quarter. Geode Capital Management LLC now owns 118,050 shares of the company’s stock worth $721,000 after purchasing an additional 84,561 shares during the period. Finally, Vanguard Group Inc. grew its stake in Actuate Therapeutics by 19.5% in the third quarter. Vanguard Group Inc. now owns 316,010 shares of the company’s stock worth $2,114,000 after purchasing an additional 51,546 shares during the period.

Actuate Therapeutics Company Profile

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.